ClinicalTrials.gg
CompletedNCT06685341Updated Nov 12, 2024

PK/PD Study of YZJ-1139

A Phase 1 interventional study of YZJ-1139 and Placebo in Insomnia, sponsored by Shanghai Haiyan Pharmaceutical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-11-12.

Sponsored by Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years 8 months after the study started (first participant enrolled Mar 2019, registered Nov 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China — 82 open to participants now, 88 under way, 2 of them phase 3. Sleep Initiation and Maintenance Disorders · China.

Enrollment
148th of 162
20 · median 88
Started
2019
with 6 others
Phase 1
13 of 198
1 open now
Registered
132nd of 198
by date
Lead sponsor
9 of 198
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

Among the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, this one is the 148th largest by enrollment of the 162 interventional ones that give a count, is one of 7 that started in 2019, is one of 13 in phase 1, and was the 132nd registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

82 of the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, or all of them as a file.
02

Study summary

Primary Objective: To determine the dose-response relationship of YZJ-1139 in young and elderly Chinese subjects after a single oral administration of different doses, and to compare it with zolpidem at clinical doses.

Secondary Objective: To investigate the safety and tolerability of YZJ-1139 in young and elderly Chinese subjects after a single oral administration of different doses, and to compare it with zolpidem at clinical doses.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Young adults and elderly Chinese healthy subjects, both male and female;
  2. Age: [young adult group] 18-45 years old (including the threshold value); [Elderly group]65\~75 years old (including the cut-off value);
  3. Body weight [only for young adults]: ≥50kg, : 18\~28kg/m2 (including the threshold value);
  4. Understand and sign the to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. History of heart, liver, lung, kidney, digestive tract, blood system, neuropsychiatric system and other diseases, including anxiety and depression, that researchers deem ;
  2. Comprehensive physical examination, neurological examination, laboratory examination, examination, etc. indicate that the subject has abnormalities that are judged by the researcher as clinically significant;
  3. Poor compliance with the pharmacodynamics training before administration;
  4. Have taken any medication in the two weeks prior to study administration, and the investigator judges it may affect the evaluation results;
  5. History of food and drug allergy or allergic reaction that the researcher determines to be clinically significant;
  6. Serological examination (, anti-, anti-, TP-Ab) with positive results;
  7. History of alcohol or drug abuse within the year prior to study administration that the investigators believe may have affected the results assessed in this study;
  8. Frequent (> 1 time per month) use of hypnotic drugs, and screening and baseline benzodiazepine urine screening positive;
  9. Participants who need to work night shifts, stay up late, or stay at least 3 time zones away from the study site within 2 weeks before and during the study;
  10. Subjects who could not maintain a regular sleep and rest schedule (get up at 6-8 am and go to sleep at 10-12 PM) within 1 week before and during the study and who were judged by the investigator to be likely to affect the results of this study;
  11. Those who could not quit smoking and alcohol drinking as required during the study period or whose carbon monoxide breath test detected >7 ppm during the screening period (further confirmation by urine cotinine test if deemed necessary by the investigators);
  12. Participants who have participated in any drug clinical trial as a subject within 3 months prior to study administration;
  13. Patients who donated blood or blood products ≥400 mL or 2 units within three months prior to drug administration;
  14. Those who do not agree to avoid the use of tobacco, alcohol or caffeinated beverages, or to avoid strenuous exercise, or to avoid other factors affecting the absorption, distribution, metabolism or excretion of drugs within 24 hours before and during the trial;
  15. Don't agree or is unable to refrain from eating grapefruit or other related tropical fruits and beverages and from using St. John's Wort during the 24 hours prior to the first dose and during the study period;
  16. Women who are pregnant or nursing, or who test positive for serum HCG before trial administration, or who cannot/do not use investigator-approved during the study as required;
  17. Those with abnormal cognitive function assessment ( less than 26 points) and judged by the researchers to be clinically significant;
  18. Subjects deemed unsuitable for this clinical study by the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Drug: YZJ-1139 high dose group

    Subjects will be into two groups:Young adult subjects and elderly subjects

    Drug: YZJ-1139

  • Experimental
    Drug: YZJ-1139 low dose group

    Subjects will be into two groups:Young adult subjects and elderly subjects

    Drug: YZJ-1139

  • Placebo comparator
    Drug: Placebo

    Drug: Placebo

  • Active comparator
    Drug: Zolpidem

    Drug: Zolpidem

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax of YZJ-1139、zolpidem

    Cmax is defined as the maximum concentration of drug

    Time frame: From Day 1 to Day 2 post single dose;up to 4 weeks

  2. AUCinf of YZJ-1139、zolpidem

    AUCinf is defined as the concentration of drug extrapolated to infinite time

    Time frame: From Day 1 to Day 2 post single dose;up to 4 weeks

  3. AUClast of YZJ-1139、zolpidem

    AUClast is defined as the concentration of drug from time zero to the last observable concentration

    Time frame: From Day 1 to Day 2 post single dose;up to 4 weeks

  4. Tmax of YZJ-1139、zolpidem

    Tmax is defined as the time (observed time point) of Cmax

    Time frame: From Day 1 to Day 2 post single dose;up to 4 weeks

  5. t1/2 of YZJ-1139、zolpidem

    Time frame: From Day 1 to Day 2 post single dose;up to 4 weeks

  6. CL/F of YZJ-1139、zolpidem

    CL/F is defined as the apparent oral clearance following administration of the drug

    Time frame: From Day 1 to Day 2 post single dose;up to 4 weeks

  7. Vz/F of YZJ-1139、zolpidem

    Vz/F is defined as the apparent volume of distribution of the drug

    Time frame: From Day 1 to Day 2 post single dose;up to 4 weeks

  8. Left and right saccade peak velocity (SPV) of Eye Movements

    Instruct the subject to fix their gaze on the red light spot on the LED display and move their eyes with the light spot. During the test, the head and body must remain still. The test consists of the following two parts, each lasting 2 minutes. Between the two parts, the subject should rest for a certain period of time based on their level of fatigue. Part 1: Scanning eye movements Part 2: Smooth pursuit eye movements.

    Time frame: From Day 1 to Day 2 post single dose;up to 4 weeks

  9. left and right saccade accuracy rate (SacAcc) of Eye Movements

    Instruct the subject to fix their gaze on the red light spot on the LED display and move their eyes with the light spot. During the test, the head and body must remain still. The test consists of the following two parts, each lasting 2 minutes. Between the two parts, the subject should rest for a certain period of time based on their level of fatigue. Part 1: Scanning eye movements Part 2: Smooth pursuit eye movements.

    Time frame: From Day 1 to Day 2 post single dose;up to 4 weeks

  10. Left and right saccade eye movement response time (SacRT) of Eye Movements

    Instruct the subject to fix their gaze on the red light spot on the LED display and move their eyes with the light spot. During the test, the head and body must remain still. The test consists of the following two parts, each lasting 2 minutes. Between the two parts, the subject should rest for a certain period of time based on their level of fatigue. Part 1: Scanning eye movements Part 2: Smooth pursuit eye movements.

    Time frame: From Day 1 to Day 2 post single dose;up to 4 weeks

  11. Smooth eye movement to the left and right (Smooth) of Eye Movements

    Instruct the subject to fix their gaze on the red light spot on the LED display and move their eyes with the light spot. During the test, the head and body must remain still. The test consists of the following two parts, each lasting 2 minutes. Between the two parts, the subject should rest for a certain period of time based on their level of fatigue. Part 1: Scanning eye movements Part 2: Smooth pursuit eye movements.

    Time frame: From Day 1 to Day 2 post single dose;up to 4 weeks

  12. Body Sway

    The subject takes off their shoes, spreads their feet shoulder-width apart, and stands on a flat ground 120 cm away from the measuring device. They close their eyes and stand for 2 minutes, and the test measures the body sway amplitude (mm) of the subject during the 2-minute closed-eye period. The test evaluates the subject's postural balance

    Time frame: From Day 1 to Day 2 post single dose;up to 4 weeks

  13. Simple response time of Choice Reaction Time Test

    The test lasts for 1 minute. During the test, there is a vertical line in the center of the screen. On both sides of the screen, random "left" or "right" words will appear. The participants are required to ignore the word meanings and click the "right" or "left" key based on the word's position.

    Time frame: From Day 1 to Day 2 post single dose;up to 4 weeks

  14. Simple response accuracy rate of Choice Reaction Time Test

    The test lasts for 1 minute. During the test, there is a vertical line in the center of the screen. On both sides of the screen, random "left" or "right" words will appear. The participants are required to ignore the word meanings and click the "right" or "left" key based on the word's position.

    Time frame: From Day 1 to Day 2 post single dose;up to 4 weeks

  15. Selective response time of Choice Reaction Time Test

    During the test, there was a dividing line in the middle of the screen. During the test, the word "left" or "right" appeared randomly on both sides of the screen. Subjects were asked to ignore the position of the word and click the key "right" or "left" according to the meaning of the word.

    Time frame: From Day 1 to Day 2 post single dose;up to 4 weeks

  16. Selective response accuracy rate of Choice Reaction Time Test

    During the test, there was a dividing line in the middle of the screen. During the test, the word "left" or "right" appeared randomly on both sides of the screen. Subjects were asked to ignore the position of the word and click the key "right" or "left" according to the meaning of the word.

    Time frame: From Day 1 to Day 2 post single dose;up to 4 weeks

  17. The average reaction time for correct responses of Digit Symbol Substitution Test

    The test time is not more than 2 minutes, the symbol is displayed on the screen, and the subject clicks the corresponding number according to the corresponding relationship between the symbol and the number given below. After clicking or exceeding the upper limit of the reaction time, the subject automatically enters the next symbol.

    Time frame: From Day 1 to Day 2 post single dose;up to 4 weeks

  18. The number of correct responses of Digit Symbol Substitution Test

    The test time is not more than 2 minutes, the symbol is displayed on the screen, and the subject clicks the corresponding number according to the corresponding relationship between the symbol and the number given below. After clicking or exceeding the upper limit of the reaction time, the subject automatically enters the next symbol.

    Time frame: From Day 1 to Day 2 post single dose;up to 4 weeks

  19. The average reaction time for incorrect responses of Digit Symbol Substitution Test

    The test time is not more than 2 minutes, the symbol is displayed on the screen, and the subject clicks the corresponding number according to the corresponding relationship between the symbol and the number given below. After clicking or exceeding the upper limit of the reaction time, the subject automatically enters the next symbol.

    Time frame: From Day 1 to Day 2 post single dose;up to 4 weeks

  20. The number of incorrect responses of Digit Symbol Substitution Test

    The test time is not more than 2 minutes, the symbol is displayed on the screen, and the subject clicks the corresponding number according to the corresponding relationship between the symbol and the number given below. After clicking or exceeding the upper limit of the reaction time, the subject automatically enters the next symbol.

    Time frame: From Day 1 to Day 2 post single dose;up to 4 weeks

  21. The number of non-responses of Digit Symbol Substitution Test

    The test time is not more than 2 minutes, the symbol is displayed on the screen, and the subject clicks the corresponding number according to the corresponding relationship between the symbol and the number given below. After clicking or exceeding the upper limit of the reaction time, the subject automatically enters the next symbol.

    Time frame: From Day 1 to Day 2 post single dose;up to 4 weeks

  22. Immediate recall of Word Recall Test

    About 1-2 hours after dosing, First, the subjects were shown 20 unrelated words, each word for a few seconds, and then the subjects were asked to immediately recall the words they just saw. The number of correct words in instantaneous recall was recorded respectively

    Time frame: From Day 1 to Day 2 post single dose;up to 4 weeks

  23. Delayed recall of Word Recall Test

    About 1-2 hours later, the subjects were allowed to freely recall the words again, which was delayed recall; The number of correct words in delayed recall was recorded respectively

    Time frame: From Day 1 to Day 2 post single dose;up to 4 weeks

  24. Delayed recognition of Word Recall Test

    The subjects were then presented with 40 words (of which 20 were previously presented words and 20 were confounding words), and were asked to answer one by one whether they were the words they had just seen. The number of correct words in delayed extraction was recorded respectively

    Time frame: From Day 1 to Day 2 post single dose;up to 4 weeks

Secondary outcomes

  1. Adverse events (AEs)

    Time frame: From Day 1 to Day 2 post single dose;up to 4 weeks

07

Study locations

1 site
  • Beijing Tiantan Hospital, Capital Medical University
    Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Apr 2019, 1 month.

Of 23 industry-sponsored phase 1 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 4 months of starting (the median); a quarter within 1 and three quarters within 5. This study's 1 month is below that.

Counting every sponsor, half of 39 studies reached it within 5 months; a quarter within 3 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2024
First posted
Nov 12, 2024
StartActual
Mar 7, 2019
Primary completionActual
Apr 10, 2019
CompletionActual
Nov 15, 2019
Last update
Nov 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06685341
Lead sponsor
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Nov 12, 2024
Start date
Mar 7, 2019
Primary completion
Apr 10, 2019
Completion
Nov 15, 2019
Last update
Nov 12, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fazamorexant

Start the discussion